Use of an H+, K+-ATPase inhibitor in the treatment of asthma

Abstract

The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H + , K + -ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.

1 . Use of an H + , K + -ATPase inhibitor in the manufacture of a medicament for the treatment of nasal polyps.  
     
     
         2 . Use of an H + , K + -ATPase inhibitor in the manufacture of a medicament for the treatment of Widal's Syndrome.  
     
     
         3 . Use of an H + , K + -ATPase inhibitor and a glucocorticoid in the manufacture of a pharmaceutical formulation intended for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome.  
     
     
         4 . Use of an H + , K + -ATPase inhibitor and a glucocorticoid in the manufacture of a pharmaceutical formulation intended for simultaneous, separate or sequential administration in the treatment of asthma.  
     
     
         5 . Use according to  claim 3  wherein the glucocorticoid is a topically active anti-inflammatory steroid.  
     
     
         6 . Use according to  claim 4  wherein the glucocorticoid is budesonide, beclomethasone dipropionate or fluticasone propionate.  
     
     
         7 . Use according to any one of the preceding claims wherein the H + , K + -ATPase inhibitor is a compound of formula  
       
         
           
           
               
               
           
         
       
       wherein N in the benzimidazole moiety of Het 2  means that one of the ring carbon atoms substituted by R 6 -R 9  optionally may be exchanged for a nitrogen atom without any substituents; 
 R 1  and R 3  each independently represent hydrogen, alkyl, or alkoxy on the condition that R 1  and R 3  do not simultaneously represent alkoxy; and R 2  represents alkyl, alkoxy optionally substituted by fluorine, alkylthio or alkoxyalkoxy; or one of R 1  and R 3  is halogen and the other is hydrogen and R 2  is 1-morpholino, 1-piperidino or dialkylamino;  
 R 4  and R 5  are the same or different and selected from hydrogen and alkyl;  
 R 6 -R 9  are the same or different and selected from hydrogen, halogen, alkyl, alkoxy, haloalkoxy, alkylcarbonyl, and alkoxycarbonyl;  
 R 10  is hydrogen or R 10  and R 3  together complete a ring containing 6 to 8 carbon atoms; and  
 R 11  represents hydrogen, halogen or alkyl; 
 wherein the compound of formula (I) is optionally in the form of a pharmaceutically acceptable alkaline salt or in its neutral form or is a single enantiomer or a racemic mixture thereof;  
 wherein each alkyl or alkylenyl moiety has a branched or straight chain and has 1 to 6 carbon atoms.  
 
 
     
     
         8 . Use according to  claim 7  wherein the compound of formula (I) is a compound of formula  
       
         
           
           
               
               
           
         
         or an alkaline salt thereof, or the (−)-enantiomer or an alkaline salt of the (−)-enantiomer.  
       
     
     
         9 . A method for the treatment of nasal polyps which method comprises treating a subject suffering from the said condition with a pharmaceutical formulation comprising an H + , K + -ATPase inhibitor.  
     
     
         10 . A method for the treatment of Widal's Syndrome which comprises treating a subject suffering from the syndrome with a pharmaceutical formulation comprising an H + , K + -ATPase inhibitor.  
     
     
         11 . A method for the treatment of Widal's Syndrome which comprises simultaneously, separately or sequentially administration to a subject suffering from the syndrome with a pharmaceutical formulation comprising an H + , K + -ATPase inhibitor and a glucocorticoid.  
     
     
         12 . A method for the treatment of asthma which comprises simultaneously, separately or sequentially administration to a subject suffering from the syndrome with a pharmaceutical formulation comprising an H + , K + -ATPase inhibitor and a glucocorticoid.  
     
     
         13 . A method according to  claim 11  wherein the glucocorticoid is a glucocorticoid defined in  claim 5  or  6 .  
     
     
         14 . A method according to any one of  claims 9  to  13  wherein the H + , K + -ATPase inhibitor is a compound of the formula defined in  claim 7  or  8 .  
     
     
         15 . A pharmaceutical formulation for simultaneous, separate or sequential use in the treatment of Widal's Syndrome which formulation comprises an H + , K + -ATPase inhibitor and a glucocorticoid.  
     
     
         16 . A pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of asthma which pharmaceutical formulation comprises an H + , K + -ATPase inhibitor and a glucocorticoid.  
     
     
         17 . A pharmaceutical formulation according to  claim 15  or  16  wherein the glucocorticoid is a glucocorticoid defined in  claim 5  or  6 .  
     
     
         18 . A pharmaceutical formulation according to any of claims  15 - 17  wherein the H + , K + -ATPase inhibitor is a compound of the formula defined in  claim 7  or  8 .